益气活血中药在中晚期胰腺癌放化疗中的作用

作者	单位
王炳胜	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000
刘秀芳	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000
吴智群	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000
王义清	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000
付显成	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000
赵增虎	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000
丁瑞亮	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000
李成云	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000
胡世金	WANG Bingsheng, LIU Xiufang, WU Zhiqun, et al. Department of Oncology, the 251 Hospital of PLA, Hebei (075000

摘要点击次数: 1675

全文下载次数: 1357

中文摘要:

目的 :探讨益气活血中药在中晚期胰腺癌放化疗中的作用。方法 :58例中晚期胰腺癌患者随机分成两组 ,2 8例行放疗和介入化疗 (A组 ) ,与 30例放疗、介入化疗及益气活血中药并用 (B组 )进行比较。结果 :A、B两组近期有效率为 53 6%、67 6% (P >0 0 5)。腹痛、黄疸症状缓解率A组分别为 57 1%、50 0 % ,B组分别为 83 3%、76 7% ,两组比较差异均有显著性 (P <0 0 5)。消化道反应B组 ( 4例 )明显轻于A组 ( 11例 ,P <0 0 5)。 1、2年生存率A组分别为 50 0 %、2 1 4 % ,B组分别为 80 0 %、4 6 6% ,两组比较差异有显著性 (P <0 0 5)。结论 :益气活血中药能减轻放化疗所致的消化道反应 ,提高临床症状有效率 ,延长 1、2年生存期

英文摘要:

Objective: To study the effect of Qi replenishing and blood circulation activating drugs (QRBCAD) in treatment of middle advanced pancreatic cancer with radio and chemotherapy. Methods: Patients were divided randomly into two groups, 28 patients treated with radiotherapy and intervention treatment as Group A and 30 patients treated with the same therapy but with additional QRBCAD medication as the Group B, and the effects in the two groups were compared. Results: The short term effective rate in Group A and B was 53.6% and 67.6% respectively (P<0 05). The remission rates of jaundice and abdominal pain in Group A were 57.1% and 50.0% respectively, while in Group B, 83.3% and 76.7% respectively, there was significant difference between the two groups, P<0 05. The gastroenteric reaction occurred in Group B was significantly lesser than that in Group A, P<0 05. The 1 and 2 year survival rate in Group A were 50% and 21.4%, and in Group B, 80.0% and 46.6% respectively, significant difference (P<0 05) showed in comparison of the two groups. Conclusion: QRBCAD could alleviate the gastroenteric reaction caused by radio and chemotherapy, raise the clinical symptomatic effective rate of treatment, and prolong the 1 and 2 year survival rate of patients.

关闭